Discovery of a potent picolinamide antibacterial active against Clostridioides difficile.

A major challenge for chemotherapy of bacterial infections is perturbation of the intestinal microbiota. Clostridioides difficile is a Gram-positive bacterium of the gut that can thrive under this circumstance. Its production of dormant and antibiotic-impervious spores results in chronic disruption of normal gut flora, and debilitating diarrhea and intestinal infection. C. difficile is responsible for 12,800 deaths per year in the United States. Here we report the discovery of 2-(4-(3-(trifluoromethoxy)phenoxy)picolinamido)benzo[d]oxazole-5-carboxylate as an antibacterial with potent and selective activity against C. difficile. Its MIC50 and MIC90 values, documented across 101 strains of C. difficile, are 0.12 and 0.25 µg/mL, respectively. The compound targets cell-wall biosynthesis, as assessed by macromolecular biosynthesis assays and by scanning-electron microscopy. Animals infected with a lethal dose of C. difficile and treated with compound 1 had similar survival compared to treatment with vancomycin, which is the front-line antibiotic used for C. difficile infection.

[1]  Antibiotic resistance threats in the United States, 2019 , 2019 .

[2]  H. Tilg,et al.  International consensus conference on stool banking for faecal microbiota transplantation in clinical practice , 2019, Gut.

[3]  S. Mobashery,et al.  Cinnamonitrile Adjuvants Restore Susceptibility to β-Lactams against Methicillin-Resistant Staphylococcus aureus. , 2019, ACS medicinal chemistry letters.

[4]  M. Rai,et al.  Updates in Treatment of Recurrent Clostridium difficile Infection , 2019, Journal of clinical medicine research.

[5]  E. Kuijper,et al.  Clostridium difficile infection: review , 2019, European Journal of Clinical Microbiology & Infectious Diseases.

[6]  T. Louie,et al.  Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. , 2019, The Lancet. Infectious diseases.

[7]  N. Petrosillo,et al.  Novel Antimicrobials for the Treatment of Clostridium difficile Infection , 2018, Front. Med..

[8]  R. Fedorak,et al.  Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection , 2017, Open forum infectious diseases.

[9]  C. Kelly,et al.  Predictors of Early Failure After Fecal Microbiota Transplantation for the Therapy of Clostridium Difficile Infection: A Multicenter Study , 2016, The American Journal of Gastroenterology.

[10]  L. Chesnel,et al.  Mode of Action and Bactericidal Properties of Surotomycin against Growing and Nongrowing Clostridium difficile , 2015, Antimicrobial Agents and Chemotherapy.

[11]  D. Leffler,et al.  Clostridium difficile infection. , 2015, The New England journal of medicine.

[12]  M. Suckow,et al.  Discovery of antibiotic (E)-3-(3-carboxyphenyl)-2-(4-cyanostyryl)quinazolin-4(3H)-one. , 2015, Journal of the American Chemical Society.

[13]  Bo Li,et al.  Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection , 2014, Nature Communications.

[14]  P. Caspers,et al.  Investigations of the Mode of Action and Resistance Development of Cadazolid, a New Antibiotic for Treatment of Clostridium difficile Infections , 2013, Antimicrobial Agents and Chemotherapy.

[15]  A. Sonenshein,et al.  Fidaxomicin inhibits toxin production in Clostridium difficile. , 2013, The Journal of antimicrobial chemotherapy.

[16]  A. Sonenshein,et al.  Fidaxomicin Inhibits Spore Production in Clostridium difficile , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Falagas,et al.  Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. , 2012, International journal of antimicrobial agents.

[18]  J. Rood,et al.  The role of toxin A and toxin B in the virulence of Clostridium difficile. , 2012, Trends in microbiology.

[19]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[20]  Jeffrey D Goldsmith,et al.  A mouse model of Clostridium difficile-associated disease. , 2008, Gastroenterology.

[21]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[22]  H. Dupont,et al.  Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  L. Sabath,et al.  Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  D. Livermore.  Linezolid in vitro: mechanism and antibacterial spectrum. , 2003, The Journal of antimicrobial chemotherapy.

[25]  A. Tomasz,et al.  In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae , 1980, Antimicrobial Agents and Chemotherapy.